• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by BeiGene Ltd.

    5/13/25 5:53:18 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 5)


    BeiGene, Ltd.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    G1146Y101

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G1146Y101


    1Names of Reporting Persons

    Capital International Investors
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    80,458,292.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    81,647,620.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    81,647,620.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.8 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BeiGene, Ltd.
    (b)Address of issuer's principal executive offices:

    C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN KY1-1108, Cayman Islands
    Item 2. 
    (a)Name of person filing:

    Capital International Investors
    (b)Address or principal business office or, if none, residence:

    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c)Citizenship:

    N/A
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    G1146Y101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    81,647,620 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 81,647,620 shares or 5.8% of the 1,400,455,662 shares believed to be outstanding. Shares reported include 5,903,798 Depository Receipts, which represent 76,749,374 Common Stock.
    (b)Percent of class:

    5.8  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    80,458,292

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    81,647,620

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Capital International Investors
     
    Signature:Jae Won Chung
    Name/Title:Vice President and Senior Counsel II, Capital Research and Management Company
    Date:05/02/2025
    Get the next $ONC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONC

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    9/18/2025$385.00Overweight
    Barclays
    4/7/2025$312.00Outperform
    RBC Capital Mkts
    3/3/2025$207.00 → $320.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $ONC
    SEC Filings

    View All

    BeOne Medicines Ltd. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    8-K - BeOne Medicines Ltd. (0001651308) (Filer)

    12/19/25 6:01:09 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Ltd. filed SEC Form 8-K: Leadership Update

    8-K - BeOne Medicines Ltd. (0001651308) (Filer)

    12/18/25 6:02:54 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by BeOne Medicines Ltd.

    144 - BeOne Medicines Ltd. (0001651308) (Subject)

    12/15/25 4:32:14 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

    Company outlines foundational hematology leadership, multiple 2026 data catalysts, a unique global clinical development superhighway, and continued financial excellence BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, will outline the pillars of its growing global oncology leadership during its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. John V. Oyler, Co-Founder, Chairman, and CEO at BeOne, will highlight the Company's transformative leadership in treating B-cell malignancies. The presentation will feature BRUKINSA®, the global leader among Bruton's tyrosine kinase (BTK) inhibitors, as well as foundat

    1/13/26 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

    Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status High GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impact Results to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+)

    1/6/26 1:30:00 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

    BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company's website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patient

    12/23/25 6:01:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on BeOne Medicines

    Truist initiated coverage of BeOne Medicines with a rating of Buy

    11/24/25 8:30:57 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on BeOne Medicines with a new price target

    Barclays initiated coverage of BeOne Medicines with a rating of Overweight and set a new price target of $385.00

    9/18/25 8:38:35 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on BeiGene with a new price target

    RBC Capital Mkts initiated coverage of BeiGene with a rating of Outperform and set a new price target of $312.00

    4/7/25 8:43:36 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, General Counsel Lee Chan Henry sold $580,197 worth of American Depositary Shares (1,660 units at $349.52) and exercised 1,660 units of American Depositary Shares at a strike of $191.40 (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    2/6/26 4:57:20 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, General Counsel Lee Chan Henry exercised 664 units of American Depositary Shares at a strike of $191.56 and sold $220,289 worth of American Depositary Shares (664 units at $331.76) (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    1/9/26 5:15:55 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, Global Head of R&D Wang Lai was granted 427,895 units of Ordinary Shares, increasing direct ownership by 42% to 1,451,424 units (SEC Form 4)

    4 - BeOne Medicines Ltd. (0001651308) (Issuer)

    1/5/26 5:12:01 PM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONC
    Leadership Updates

    Live Leadership Updates

    View All

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

    DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

    10/21/25 8:05:00 AM ET
    $CRVS
    $DNA
    $EXEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ONC
    Financials

    Live finance-specific insights

    View All

    BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

    Third quarter total revenues increased 41% to $1.4 billion versus third quarter 2024 Global BRUKINSA® (zanubrutinib) revenues increased 51% to $1.0 billion versus third quarter 2024 Diluted GAAP Earnings per American Depository Share (ADS) of $1.09, non-GAAP diluted Earnings per ADS of $2.65 47 abstracts accepted at American Society of Hematology (ASH) Annual Meeting BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the third quarter of 2025. "These strong financial results reinforce our position as a global oncology leader with exceptional topline growth and a strong balance sheet,

    11/6/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

    Second quarter total revenues increased 42% to $1.3 billion versus second quarter 2024 Global BRUKINSA revenues increased 49% to $950 million versus second quarter 2024 Reported diluted GAAP Earnings per American Depositary Share (ADS) of $0.84, non-GAAP diluted Earnings per ADS of $2.25 Anticipate 20+ milestones in next 18 months across hematology and solid tumor pipeline BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced financial results and corporate updates from the second quarter of 2025. "Our strong second quarter performance reinforces our trajectory as a global oncology powerhouse and underscores our proven abilit

    8/6/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeiGene Announces First Quarter 2025 Financial Results and Business Updates

    First quarter 2025 total revenues increased 49% to $1.1 billion with BRUKINSA® (zanubrutinib) global sales increasing 62% to $792 million on strong demand growth versus first quarter 2024 Achieved GAAP profitability and significantly improved operating cash flow Advanced late-stage hematology and solid tumor pipelines with plan to host Investor R&D Day on June 26 Secured shareholder approval to rename the Company to BeOne Medicines Ltd. and redomicile to Switzerland BeiGene, Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025.

    5/7/25 6:00:00 AM ET
    $ONC
    Biotechnology: Pharmaceutical Preparations
    Health Care